Clinical trial
Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That…
NCT00005635 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00005635 |
|---|---|
| Title | Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2 |
| Official title | A Phase II Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of Herceptin Administered Subcutaneously in Combination With Paclitaxel in Women With HER2 Overexpressing Metastatic Breast Cancer |
| Lead sponsor | Genentech, Inc., Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, paclitaxel |
| Start date | Jan 1, 2000 |
| Primary completion | Nov 1, 2001 |
| First posted | Mar 16, 2004 |
| Last update posted | Aug 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: